Multiple biomarkers, including mismatch repair proteins, Her2 [65], and PD-L1 [66,67], assessed via biopsy samples, should be mandatory before initiating the first-line treatment in all patients with gastric cancer [68]. The gene discussed is ERBB2; the disease is gastric cancer.